119 related articles for article (PubMed ID: 8115979)
1. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
[TBL] [Abstract][Full Text] [Related]
2. [Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma].
Sciarra A; Stasi R; Stipa E; Masi M; Oliva F; Olivieri M; Perrotti A; Zaccari G; Amadori S; Papa G
Recenti Prog Med; 1995 Feb; 86(2):57-62. PubMed ID: 7754173
[TBL] [Abstract][Full Text] [Related]
3. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
5. [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H; Wang Y; Han X
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
Kalmanti M; Karamolengou K; Dimitriou H; Tosca A; Vlachonikolis I; Peraki M; Georgoulias V; Kalmantis T
Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
10. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
11. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
12. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
13. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
14. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
15. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.
Stasi R; Conforti M; Del Poeta G; Simone MD; Coppetelli U; Tribalto M; Cantonetti M; Perrotti A; Venditti A; Papa G
Haematologica; 1992; 77(6):518-21. PubMed ID: 1289190
[TBL] [Abstract][Full Text] [Related]
16. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss.
Vora S; Shetty S; Salvi V; Satoskar P; Ghosh K
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):136-40. PubMed ID: 17644242
[TBL] [Abstract][Full Text] [Related]
18. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
19. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced urticaria--activity of selected cytokines and acute phase proteins in plasma.
Czelej D; Chodorowska G; Lechowska-Mazur I
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):38-42. PubMed ID: 15314956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
